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ABSTRACT
Background: Psoriasis is a genetically complex, chronic
inflammatory skin disease. The authors have previously
identified a susceptibility locus on chromosome 19p13
(PSORS6).
Methods and results: In a follow-up linkage disequili-
brium (LD) study in an independent family based cohort,
the authors found evidence for association to a newly
discovered microsatellite at this locus (D19SPS21,
p,5.3610
25). An LD based association scan in 300 trios
revealed association to several single, single nucleotide
polymorphisms (SNPs) in one LD block. When the authors
stratified this cohort for carrying the PSORS1 risk allele at
the HLA-C locus, evidence for association became much
stronger at single SNP and haplotype levels (p values
between 1.0610
24 and 8.0610
24). In a replication study
of 1114 patients and 937 control individuals, evidence for
association was also observed after stratification to the
PSORS1 risk allele. In both study groups, logistic
regression showed evidence for interaction between the
risk alleles at PSORS1 and PSORS6. Best p values for
rs12459358 in both study groups remained significant
after correction for multiple testing. The associated LD
block did not comprise any known genes. Interestingly, an
adjacent gene, MUC16, coding for a large glycosylated
protein expressed in epithelia and of unknown function,
could be shown to be also expressed in tissues relevant
for pathogenesis of psoriasis such as skin and thymus.
Immunohistochemical analyses of skin revealed focal
staining for MUC16 in suprabasal epidermal cells. Further
functional studies are required to clarify its potential role
in psoriasis and identify the causal variant(s) at this locus.
Conclusion: The data establish PSORS6 as a confirmed
psoriasis susceptibility locus showing interaction with
PSORS1.
Psoriasis is a chronic inflammatory disorder of the
skin. The disease has a complex aetiology and
affects about 0.5–4.0% of the European and
Northern American population.
12 Even though
there is considerable evidence for genetic factors
from family and twin studies—for example, con-
cordance rate of up to 65% in monozygotic
twins—only a few susceptibility factors have been
discovered to date. While positional cloning stra-
tegies using genome wide linkage analysis (GWLA)
have allowed identification of disease causing
variants in numerous monogenic diseases, the
adaptation of this systematic approach to complex
diseases
3 has been successful in only a few instances.
In psoriasis vulgaris (PsV), the most evidentiary
linkage region is at psoriasis susceptibility locus
1(= PSORS1)on chromosome6p21.3,
4especiallyin
families with PsV manifesting at younger age
((40 years, type I psoriasis
5). At this locus, the
most consistently associated allele is the *Cw0602
allele of HLA-C gene, although the remarkably high
linkage disequilibrium (LD) at this locus has
hampered definite identification of the causative
variant.
6 In addition, more than nine psoriasis
susceptibility loci have been identified (PSORS1-9
and one further for psoriatic arthritis, PSORAS1).
Onlyatthreeloci,replicatedassociationtocandidate
genes (RAPTOR and SLC12A8) has been reported so
far (PSORS2 and PSORS5)
7–10 or several genes—for
example, LOR, LCE1C, PGLYRP, SPRR genes,
PRR9 genesandIVL—havebeen proposedtoaccount
for psoriasis susceptibility (PSORS4).
11–14 In contrast,
genome-wide association studies (GWAS) have
turned out to be a very successful approach
for many complex diseases. Recently, variants in
two genes of the IL-23R pathway were identified as
PsV susceptibility factors by two independent
groups.
15 16 Like in other HLA related complex traits,
the relative risk associated with these variants is
markedlylowerthanthatforHLA-Cassociatedallele.
It is expected that many more susceptibility alleles
with small effects contribute to the aetiology of PsV.
In this study, we describe our positional cloning
efforts at PSORS6 located on chromosome 19p13,
which we previously identified in a genome-wide
linkagescanofextendedmultiplexPsVfamiliesfrom
Germany.
17 Subsequently, we detected genetic asso-
ciation in an independent family based cohort to
two newly discovered microsatellite markers below
the linkage peak. After exploring the LD structure at
this previously poorly characterised genomic region,
we performed association studies based on the LD
structureandcouldnarrowaPsVsusceptibilityallele
to a 50 kb intergenic LD block. This finding was
replicated in a further case–control cohort. In both
groups, association was stronger in patients carrying
the PSORS1 risk allele, suggesting interaction
between both loci. Strong LD hampered further
refinement of the locus, which contains no known
gene. One of the neighbouring genes (MUC16),
though, showed expression in several tissues rele-
vant for PsV and the product of this gene showed
immunostaining in epidermal cells. We speculate
that this locus contains yet unidentified regulatory
elements influencing other genes in this genomic
region.
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Patients
The 210 nuclear families with and without 90 additional trios,
respectively, were the ones described previously.
18 19 In brief, all
index cases had an early onset form of psoriasis vulgaris with
medium (SD) age of onset of 16.2 (9.1) years; 53.3% of index
patients were male. In 61% of trios, the father and/or the
mother were also affected by psoriasis.
The case cohort consisted of 1114 single patients with PsV
and was recruited through dermatology clinics at three psoriasis
rehabilitation hospitals and at three university hospitals.
20 An
early onset form of psoriasis (type I) was diagnosed in all but 75
patients. The medium age of onset was 23.2 (11.9) years, and
21.4 (9.5) years in type I patients. The majority of patients
suffered from plaque type of PsV. We excluded all patients with
signs of psoriatic arthritis until the time of recruitment when
medium age was 48.2 (13.4) years; 62% of patients were male.
The 937 control probands had no PsV and no history or signs
of inflammatory joint disease at the time of recruitment, when
their mean age was 31.6 (10) years. All were German (white)
healthy blood donors; 58% of probands were male.
The studies were approved by the ethical committees of the
University of Erlangen-Nuremberg and of the University of
Mu ¨nster. Written informed consent was obtained from each
patient and control proband before enrolment. The investiga-
tions were conducted according to Declaration of Helsinki
principles.
Microsatellite analyses
To identify new microsatellites within the linkage region, we
used the program Tandem Repeat Finder (Benson
21; http://
tandem.bu.edu/trf/trf.html (accessed April 2002)). In order to
have markers with fewer alleles, we chose a set of 24 evenly
spaced microsatellites that were mostly tetra- or penta-nucleo-
tides or had in the case of di-nucleotides ,15 repeats in the
database sequence. Primers were chosen with the program Primer
3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi
(accessed April 2002)); all forward primers were labelled with
one of three fluorescent dyes (FAM, HEX, TET). The micro-
satellites were arranged in two different panels according to
magnitude and labelling of the polymerase chain reaction (PCR)
product. PCRs were performed as previously described.
18 For eight
microsatellites, we obtained either no PCR product or the
corresponding microsatellite was not polymorphic. Therefore 16
microsatellites (supplemental table 1) remained that could be
genotyped in 210 trios; these markers cover a genomic region of
,1.3 MbaroundthepreviouslydescribedmicrosatellitesD19S922,
D19S865 and D19S916.
17 PCR products were pooled and size
fractionated on an ABI3100 DNA analysis system (Applied
Biosystems, Foster City, California, USA) along with a TAMRA
labelled standard. Electrophoresis files were analysed with
Genotyper and/or Genemapper software (Applied Biosystems).
Consistency for correct allele sizes was ensured by simultaneous
genotyping of previously defined DNA controls. The overall
genotyping rate was 93.3%. Genotypes were checked for
Mendelian inheritance, while the transmission disequilibrium test
(TDT)asimplementedinthefamilybasedassociationtest(FBAT)
software
22 was used to test for association under default options.
Sequencing, LD structure and SNP genotyping
In the genomic region of D19SPS20 and D19SPS21, about
225 kb of sequence were analysed for conservation with mouse
sequence and the sequences of other species (as identified with
the feature of University of California Santa Cruz (UCSC)
genome browser at http://genome.ucsc.edu/ (accessed
November 2005)). Those sequences exhibiting evidence for
conservation were selected; primers for coverage of these
sequences were chosen with Primer 3. In 32 independent
psoriasis patients chosen from affected individuals of the trios,
105 PCR products were amplified and sequenced as previously
described.
9 In order to uncover the LD structure of this region,
we filtered for single nucleotide polymorphisms (SNPs) with a
minor allele frequency (MAF) of .0.10.
Based on the LD structure, we chose a first set of 44
haplotype tagging SNPs (htSNPs) and genotyped them as
TaqMan assays in the 300 trios. After first evidence for
association of psoriasis to several single SNPs, we chose 24
independent individuals of this study group that were either
homozygous (n=19) or heterozygous (n=5) for a haplotype
consisting of several associated SNP alleles within the LD block.
We sequenced the probands for a further 29 PCR products
within/neighbouring this LD block to identify further possible
risk variants. In the meantime the first HapMap data had been
made publicly available. We combined information from both
sources to choose an appropriate and redundant set of 30
further htSNPs with different programs such as SNPtagger,
23
Ldmax
24 and Haploview.
25 These SNPs were also genotyped in
300 trios with two different methods—SNPlex or TaqMan
(Applied Biosystems)—as recommended by the manufacturer.
For data analysis, only SNPs with a MAF .5%, no deviation
from Hardy–Weinberg equilibrium (HWE) (p values .0.01) and
no excess of Mendelian errors were accepted. For the remaining
63 SNPs (supplemental table 2) overall genotyping rate was
96.0%. For two SNPs that were genotyped with both methods
(SNPlex and TaqMan) the concordance rate was .99.5%. For
each SNP a subset of genotypes was confirmed through direct
sequencing in 24–32 randomly chosen probands. Genotyping of
the same DNA of a control individual was part of every single
experiment and resulted in consistent genotypes for all SNPs
included in this study.
The case control study—1114 PsV patients and 937 control
probands—were genotyped for nine SNPs in the associated LD
block (rs8100377, rs6511831, rs12459358, rs8109594, rs8102472,
rs7249334, rs10413384, rs2591618 and rs28699225) either with
SNPlex or TaqMan. Similarly, no SNP showed significant
deviation from HWE. Overall genotyping rate was 97.6%. SNPs
of two genes of the IL-23R pathway, namely IL12B and IL23R,
were genotyped as recently described.
20
LD analysis, statistical and haplotype analysis
LD of tagging SNPs was determined with the software
Haploview.
25 LD blocks were basically defined according to the
model ‘‘Solid Spine’’. In order to be able to include several sibs of
one family, we used the TDT as implemented in the association
methodforsingleSNPs and haplotypes as describedin Becker and
Knapp.
26 This method can be viewed as a generalisation of the
TDT.
27 Haplotypes were calculated within the predefined LD
blocks. In the case–control study, association with single SNPs
was tested with Armitage’s trend test.
28 Odds ratios (ORs) and
their confidence intervals were determined for single SNP alleles
with final p values of ,0.05. Haplotypes within the blocks were
calculated with the same method as in trios.
26
In order to compare results from the family study (TDT
statistics) with those of case–control studies, we used the model
of Kazeem and Farrall
29 and estimated ORs for SNP rs1249358
from the TDT data and calculated a combined OR of both
studies, family based and case–control.
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J Med Genet 2009;46:736–744. doi:10.1136/jmg.2008.065029 737Stratification for PSORS1 and interaction with other psoriasis
susceptibility alleles
For stratification for the PSORS1 risk allele, we used an estimate
as previously described.
20 In order to test for interaction in the
case–control study between known psoriasis susceptibility loci
and the risk alleles identified at PSORS6, we used logistic
regression as suggested by Cordell and Clayton.
30 We compared
a model of three degrees of freedom with an interaction
parameter and one parameter for each, the PSORS1 risk
haplotype and the SNP rs1245938 at PSORS6, to a model of
two degrees of freedom with just the parameters for the
markers. In the nuclear families, we compared the number of
transmissions/non-transmissions of rs1245938 at PSORS6 after
stratification of index cases for carrying the PSORS1 risk
haplotype.
In order to test for possible interaction of susceptibility
factors of the IL-23R pathway and the PSORS6 variant
rs1249358 in the family cohort, we used the variant of IL-23R
pathway that was most highly associated in the trios
(rs6887695) and tested for interaction with the program
UNPHASED.
31
Correction for multiple testing
In the family based cohort, we performed an explorative study
with microsatellites with few alleles (mostly two to three
frequent ones) in order to exclude/confirm a role of PSORS6 in
psoriasis. Due to the explorative character of this study, we did
not correct for the number of markers/alleles tested. In order to
correct for the number of SNPs tested in the second association
study, also accounting for LD, we applied a Monte Carlo
simulation procedure for the most strongly associated SNP.
26
Taking into account that we considered the complete sample as
well as the samples stratified according to PSORS1 and the
IL12B variant, we applied a further Bonferroni correction by a
factor of 3. To account for the fact that we used different
methods to do analysis stratified for PSORS1 on the one hand
and for IL12B on the other hand (also we did apply only one
kind of analysis in each situation), we applied a further
Bonferroni correction by a factor of 2.
In order to find out whether the strongly associated SNPs
might be the disease-causing variant(s) or whether there is
evidence for other not yet identified variants, we performed
haplotype analyses. This analysis again was regarded as
explorative.
In silico analyses
We performed in silico analyses to identify potential unknown
genes within the associated region. Several gene prediction
programs were used: GrailEXP, Genscan and Augustus (
32 33
http://augustus.gobics.de/ (accessed November 2005)).
Furthermore, we analysed human expressed sequence tags
(ESTs) within this interval that were annotated at the UCSC
genome browser (http://genome.ucsc.edu/ (accessed November
2005)) and performed blast analysis (http://www.ncbi.nlm.nih.
gov/blast/Blast.cgi (accessed November 2005)) to confirm their
location within this region. Human and mouse sequences were
compared with the Pipmaker software.
34 In addition, we used
two further features annotated in the UCSC genome browser:
‘‘mouse chain alignments’’ and ‘‘mouse alignment net’’.
35 Finally,
theregionsthat showed evolutionaryconservationwere screened
for protein sequences with protein blast (blastx, http://www.
ncbi.nlm.nih.gov/blast/Blast.cgi (accessed November 2005)).
Transcription analyses
Genomic intervals that contained in silico gene predictions and
showed evolutionary conservation were considered for reverse
transcriptase PCR (RT-PCR) based transcription screening. We
used a set of primers within these intervals and performed
systematic RT-PCRs from cDNA of four different tissues
relevant for psoriasis and/or other autoimmune diseases: two
cDNAs from skin, blood leucocytes and thymus, respectively,
and one from thyroid. Furthermore, we chose forward primers
for different RT-PCRs covering the 59 region of a differential
transcript predicted by Genscan. This transcript was longer in
the 59 region than the longest annotated mRNA of MUC16, and
reached into our associated genomic interval. In combination
with reverse primers within the 59 region of the mRNA of
MUC16, we performed again exon overlapping RT-PCRs.
Moreover, exon-overlapping primers derived from 59 exons of
the MUC16 RefSeq sequence were selected.
One positive (GAPDH) and one negative control (an intronic
fragment of PTPN22) were included in each experiment. RT-
PCRs were performed with invitrogen taq polymerase
(Invitrogen, Carlsbad, California, USA) under standard condi-
tions with a touch-down PCR program; each experiment was
performed with or without betain. Successfully amplified PCR
products of the expected size were sequenced.
Analysis of copy number variation using quantitative PCR
In order to analyse the genomic region of BAC RP11-79F15, a
bacterial artificial chromosome (BAC) that was previously
reported to show copy number variation (CNV; Database of
Genomic Variation,
36), we developed two different quantitative
PCRs (qPCR), one within the gene MBD3L1, the other one
within the non-repetitive 59 part of MUC16 gene. Genomic
copies of the target regions were compared to the housekeeping
gene albumin. qPCRs were set up as previously described.
37
Sequences of primers and probes are available upon request.
Ninety-four psoriasis patients and 94 control individuals were
tested for CNV at MBD3L1, and 94 control individuals for CNV
at MUC16. We obtained reliable genotypes (defined as SD
,0.15) in 97.9% or 98.9% of individuals, respectively.
Immunohistochemistry
Immunohistochemical analyses were performed with antibody
OC125 (MUC16) purchased from Dako (Carpinteria, California,
USA) according to the modified ABC method (avidin biotin
peroxidase complex) as recommended by the manufacturer.
Twelve skin biopsies—10 of psoriasis vulgaris patients and two
of control probands—were analysed.
RESULTS
Ten out of 16 microsatellites had two frequent alleles (.5%), a
further four markers had three, and two microsatellites had four
or five frequent alleles, respectively. FBAT statistics showed
strong association with one allele of D19SPS21 in the 210 trios
(p=5.3610
25, fig 1). Of the neighbouring microsatellites,
D19SPS20 was less strongly associated (p,2.7610
22).
Sequencing of the 32 individuals in an interval of about
225 kb surrounding D19SPS20 and D19SPS21 identified 87
frequent SNPs with a MAF of .0.10, corresponding to a density
of one SNP every 2.6 kb. Haploview identified nine larger LD
blocks (supplemental fig 1). One area located between blocks IV
and V exhibited remarkably reduced LD and also a lower SNP
density. To cover this region better we sequenced additional
PCR fragments in a further set of 24 independent PsV patients,
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type (see below) and combined these data with that from
HapMap published in the meantime. This resulted in a dense
coverage of 63 successfully genotyped haplotype tagging SNPs,
one every 3.3 kb.
In the 300 trios, association to several single SNPs in the
centre of the interval—SNPs 24 to 41, corresponding to block
V—was the main finding (fig 2, supplemental table 2). Also at
the haplotype level, association was observed in blocks IV to VI
(fig 3). However, in comparison with findings in the micro-
satellite scan, evidence for association was less significant
(p,0.006). After stratification of index patients of all trios to
the PSORS1 risk allele, association findings were substantially
stronger in the trios with index patients carrying the PSORS1
risk allele (= PSORS1 positive trios; fig 2 and 3), while no
evidence for association was identified in PSORS1 negative
trios. Four single SNPs in LD block V (rs6511838, rs12459358,
rs8102472, rs7249334) gave the strongest association signal; the
corresponding transmission ratios were 88:46, 92:47, 80:41 and
80:42 (T:U), respectively (p values between 1.0610
24 and
8.0610
24 (fig 2)). Similarly, a frequent haplotype (32.0%)
within this LD block, which was a combination of mostly
associated alleles (TAGCCGTACGACTCGGCG), showed a
similarly skewed transmission ratio of 37:12 (p=1.0610
24
(fig 3)). None of the further variants of this haplotype identified
through sequencing showed association indicating that (one of)
the four variants or a yet unidentified one(s) that are in strong
LD with them are disease-causing. After correction for the
number of SNPs tested, the best single marker association p
value of p=0.000132 for rs12459358 increased to 0.0046. The
further Bonferroni correction in order to correct for the different
stratification strategies resulted in a p value of 0.0276 in the
family sample.
In order to replicate our association finding, we analysed an
independent case–control study of 2051 individuals for nine
single SNPs within LD block V. Initially, we did not observe
evidence for association of PsV to any of the single SNPs or the
corresponding haplotypes (tables 1 and 2). After stratification to
the PSORS1 risk allele, though, three SNPs (rs12459358,
rs8102472 and rs7249334) showed large allele frequency
differences of about 8% resulting in significant p values of
5.0610
23, 0.013 and 0.027 in carriers of the PSORS1 risk allele
(table 1). The corresponding haplotype TAGGTAGCG within
block V had a frequency of 31.8% in these latter patients and of
24.7% in the corresponding control individuals (p=0.012; OR
1.42, 95% CI 1.05–1.93) (table 2). Since the case–control study
was regarded as a replication study, we initially did not correct
for the number of tests performed. However, the best p value of
0.005 (for rs12459358) would withstand MC based correction
for the number of SNPs tested (p=0.034; same method as for
the family sample) as well as Bonferroni correction (p=0.045).
We chose SNP rs12459358 to compare association effects of
both studies by the model of Kazeem and Farrall.
29 While the
OR for rs12459358 in the subset of PSORS1 positive trios was
estimated to be 2.6¡0.20 and therefore higher than the one of
the case–control study, the combined OR was estimated to be
1.78¡0.11. Although we detected evidence for significance of
this latter value (x
2=25.37, p,4.7610
27), test of homogeneity
of ORs indicated significant heterogeneity.
Our interaction analysis in the case–control study with regard
to risk alleles of PSORS1 and PSORS6 revealed that the
interaction parameter significantly improved the model fit
(p=0.044). We have thus significant deviation from a multi-
plicative two marker model. In addition, the skewed transmis-
sion ratio in the independent family based cohort was even
more significant (p=1.65610
23), indicating evidence for inter-
action in both, the family and the case–control groups. In
contrast, no evidence for interaction between the PSORS6 risk
allele and variant rs6887695 of the IL12B gene was detected
(p=0.41).
The analyses with gene prediction programs did not provide
interesting candidate genes/regions. Genscan predicted six
hypothetical genes plus additional 59 exons of the annotated
gene MUC16. These six gene suggestions were unlikely to be
real since almost none of the exons overlapped evolutionary
conserved regions. Further in silico analyses of annotated ESTs
showed that only 13 of the 44 ESTs revealed a satisfying
alignment with the region of interest and these mostly
overlapped with one of the many repetitive elements.
Alignment of corresponding human and mouse genomic
sequence showed 20 regions of good conservation with
similarities to known genes from unlinked regions.
Figure 1 Results of family based
association test (FBAT) statistics for 16
microsatellites. Line with rhombi
represents results. Stars indicate relative
localisation of previously analysed
microsatellites (Lee et al
17; *D19S922,
**D19S916, ***D19S865 and
****D19S221).
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for any of the regions from skin, thyroid, thymus and/or blood
leucocytes. Also the predicted additional 59 exons of the
annotated MUC16 mRNA were undetectable in cDNA from
these tissues. In contrast, we detected transcription of MUC16
mRNA in all tissues but leucocytes (fig 4). These results were
confirmed in independent experiments using different primers
(data not shown). Accordingly, immunohistochemical analyses
using an antibody against MUC16 showed immunostaining in
epidermal cells of all 12 skin biopsies investigated. In addition,
several individuals—four patients and one control individual—
showed focally more intensive staining in several areas of basal
and suprabasal epidermal cells (fig 5).
Finally, we were able to develop two robust assays for
detecting variation in copy number in the region of BAC RP11-
79F15, overlapping the 39 region of MUC16 telomeric to the
associated region. This region was previously reported to be
polymorphic for copy number in the European population.
However, we did not find any loss or gain of copy number in
any of the analysed 184 and 93 individuals, respectively.
Additional data from Affymetrix 6.0 SNP chips of 158
individuals analysed with the Affymetrix Console 2.1 did not
show CNV of this region (data not shown). We conclude that
the region of this BAC shows no significant variation in copy
number, at least in the German population.
DISCUSSION
The adaptation of the classical linkage analysis paradigm,
initially developed for gene identification of Mendelian dis-
orders, to complex traits is based on an initial genome-wide
linkage scan followed by LD studies in regions showing evidence
for linkage. This strategy has been successful for several diseases
such as Crohn’s,
33 8asthma
39 and sarcoidosis
40 to name a few.
We followed this strategy with an initial genome-wide linkage
scan of 32 extended PsV families with multiple affected
individuals. This study identified two major linked regions,
one at the HLA locus on chromosome 6 (PSORS1) and one on
chromosome 19p13 (PSORS6) (Lee et al
17). PSORS1 is the major
PsV susceptibility locus and has been replicated in all linkage
studies to date, while the PSORS6 has only been replicated in a
study from the UK.
41
We performed a systematic LD study in the region of the
linkage peak at psoriasis susceptibility locus 6 (PSORS6). When
scanning a 1.3 Mb region from the core linkage interval using 16
informative microsatellites with reduced heterozygosity, we
were able to identify a strong association to one allele of
microsatellite D19SPS21. Since the neighbouring marker
D19SPS20 was also associated, we focused our efforts on this
region of about 250 kb. At the time of discovery, the LD
structure of this region was poorly characterised. We therefore
identified SNPs in 32 patients, determined the LD structure, and
confirmed it by genotyping tagging SNPs in 600 independent
parents of the trio cohort. The structure proved to be
concordant with that later reported by HapMap.
42 In the
TDT analysis in 300 trios we found association with several
SNPs from the same 50 kb haplotype block. Similarly, the
haplotype encompassing the same alleles was also associated.
The association signals increased after stratification for the
PSORS1 risk allele on chromosome 6p, suggesting that both risk
factors interact.
To verify these findings we genotyped tagging SNPs for this
haplotype in an independent case control cohort of 1114
patients and 937 controls. After stratification for PSORS1 the
association was again significant, although less strongly.
Nevertheless, we consider this a successful replication. While
we found evidence for interaction with the PSORS1 risk allele, a
similar effect of variants of the IL-23R pathway was not
detectable. The combined OR of both study groups for one SNP
at PSORS6 was estimated to be 1.78¡0.11. This magnitude of
susceptibility is in the range observed in non-HLA loci in
Figure 2 Results of transmission disequilibrium test (TDT) statistics for the 63 haplotype tagging single nucleotide polymorphisms (SNPs). (a)
Relative locations of SNPs between bp 8904347 and 9112258 on chromosome 19 (hg18). Stars indicate the location of the two associated
microsatellites (*D19SPS20, **D19SPS21). (b) The blue line displays negative logarithms of p values ,0.2 in all trios, the magenta line the ones in
trios with index patients carrying the PSORS1 risk allele. The green line indicates the significance level of p,0.05, curly braces affiliation to a haplotype
block as shown in fig 3 and supplemental table 2.
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recently described and well replicated variants in genes of the IL-
23R pathway
15 16 showed a similar effect size in our German
case control cohort (OR 1.50).
20
Interaction between PSORS1 and one of the further psoriasis
susceptibility loci has been described previously for PSORS4 on
chromosome 1q21.
43 In our study, stratification according to
PSORS1 indicated that PSORS6 was only relevant in PSORS1
carriers. Indeed, we did not observe association of psoriasis with
POSRS6 in non-carriers of the PSORS1 risk allele. Thus, we can
speak of epistasis, and our model is neither multiplicative nor
additive. Our family based sample contained some families with
more than one affected child. For this configuration, a
derivation of the exact disease model remains a challenge.
Although chromosome 19 has about twice the gene density of
the genome average,
44 our results did not map to any known
coding region. Many non-coding regions, though, harbour
regulatory elements regulating expression of adjacent genes.
Interestingly, we showed that one of the neighbouring genes,
mucin 16 (MUC16), of unknown function is expressed in several
tissues that are relevant for psoriasis and/or other autoimmune
diseases such as skin, thymus, and thyroid. Expression in other
epithelia such as ocular surfaces (cornea, conjunctiva), respira-
tory tract and vagina has been described.
45 46 The highly
glycosylated MUC16 has long been known as a tumour marker
indicating recurrence of ovarian cancer and preceding cancer
genesis
47 and is often referred to as antigen CA125.
48 Our
immunohistochemical analysis revealed weak general staining
of the epidermis with focally increased signals in suprabasal cells
of the suprapapillary epidermis. This location coincides with the
main hyperproliferative zone in psoriatic skin, while in normal
epidermis proliferation is restricted to basal cells.
49 Our
results show a discrepancy with previously performed micro-
array analyses that did not show differential expression.
50–52
Figure 3 Genomic region of interest, linkage disequilibrium (LD) structure in trios, and results of transmission disequilibrium test (TDT) statistics for
haplotypes within seven haplotype blocks. (a) Name, exon structure and orientation of RefSeq genes. (b) Pairwise LD plot for the 63 single nucleotide
polymorphisms (SNPs) based on data of trios with index patients carrying the PSORS1 risk allele. Each square plots the level of LD between a pair of
sites in the region; comparisons between neighbouring sites lie along the upper most line. Red colouring indicates strong LD, light red less strong LD, a
shadow of red intermediate LD, and white indicates weak LD. The areas limited by a black line show the seven haplotype blocks basically defined by
the model ‘‘Solid Spine’’. (c) Results of FAMHAP statistics for haplotypes with .30 informative transmissions in all trios; shown are results within the
seven haplotype blocks in all trios (blue) and in trios with index patients carrying the PSORS1 risk allele (magenta). The green line indicates the
significance level of p,0.05, stars the location of the two associated microsatellites (*D19SPS20, **D19SPS21). For p values .0.15, a negative
logarithm of 0.15 is shown.
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the suprabasal layer.
Interestingly, retinoids and glucocorticoids, which are effec-
tive therapeutic agents in psoriasis, enhance MUC16 expression
in eye epithelia.
53–55 Furthermore, a role of MUC16 in protection
against pathogen adherence
56 renders it an even more interesting
gene for psoriasis with regard to the HLA-C risk allele. Especially
PSORS1 positive patients are prone to develop the guttate form
of psoriasis,
57 a form that has been strongly associated with
throat infections with b-haemolytic streptococci.
58 Recently a
variant in the 59 region of another member of the mucin family,
MUC19, has been newly identified to be relevant in the
pathogenesis of Crohn’s disease.
59 This might indicate a more
general role of these epithelial proteins in the pathogenesis of
diseases with compromised barrier function. Nevertheless, we
cannot exclude that expression of other genes in this genomic
region might also be affected. To analyse this aspect exhaust-
ingly, a combination of several functional analyses such as
qPCR, expression studies of further positional candidates, for
example, would be necessary.
Besides SNPs, copy number variation (CNV) has been
recognised as a new class of potential risk factors in complex
diseases. In psoriasis, a CNV comprising the b-defensin gene
cluster was reported as a risk factor in various European cohorts,
including our own study group.
60 Iafrate et al
36 reported a
frequent CNV of the adjacent telomeric region encompassing
the 39 parts of MUC16 gene as well as MBD3L1 and ZNF558
genes. Since LD of the associated SNPs with this CNV could not
be excluded, we developed two qPCR assays using an established
approach
37 and genotyped part of the case–control cohort.
However, we could not detect this CNV in our population.
Table 1 Allele frequencies of the associated tag SNP in (A) 1114 psoriasis patients and 937 controls and (B) carriers of the PSORS1 risk allele (633
psoriasis patients and 131 control individuals) and results of x
2 statistics
SNP rs-ID Allele
(A) (B)
Controls
Psoriasis
vulgaris
p Value
Controls
Psoriasis
vulgaris
p Value OR (95% CI) n (%) n (%) n (%) n (%)
rs8100377 T 1630 (88.6) 1944 (88.2) NS 226 (89.7) 1109 (88.6) NS NA
C 210 (11.4) 260 (11.8) 26 (10.3) 143 (11.4)
rs6511831 A 831 (45.0) 1051 (48.1) NS 112 (43.8) 594 (48.0) NS NA
G 1015 (55.0) 1135 (51.9) 144 (56.3) 644 (52.0)
rs8109594 G 1470 (79.5) 1714 (81.4) NS 206 (79.8) 964 (80.2) NS NA
A 378 (20.5) 392 (18.6) 52 (20.2) 238 (19.8)
rs12459358 G 1114 (61.1) 1368 (62.8) NS 141 (55.1) 793 (64.4) 0.005 1.47 (1.12 to 1.94)
A 708 (38.9) 810 (37.2) 115 (44.9) 439 (35.6)
rs8102472 T 537 (30.9) 700 (33.4) NS 63 (26.0) 405 (34.2) 0.013 1.48 (1.08 to 2.02)
C 1199 (69.1) 1398 (66.6) 179 (74.0) 779 (65.8)
rs7249334 A 652 (35.2) 779 (37.0) NS 80 (30.8) 461 (38.2) 0.027 1.39 (1.04 to 1.85)
G 1198 (64.8) 1325 (63.0) 180 (69.2) 747 (61.8)
rs10413384 G 1458 (79.1) 1732 (78.4) NS 198 (76.2) 992 (78.9) NS NA
A 386 (20.9) 478 (21.6) 62 (23.8) 266 (21.1)
rs2591618 C 1080 (58.1) 1307 (58.9) NS 144 (55.0) 759 (60.2) NS NA
T 778 (41.9) 913 (41.1) 118 (45.0) 501 (39.8)
rs28699225 G 1461 (79.7) 1739 (79.0) NS 194 (77.6) 996 (79.9) NS NA
A 371 (20.3) 461 (21.0) 56 (22.4) 250 (20.1)
CI, confidence interval; NA, not applicable; NS, not significant; OR odds ratio; SNP, single nucleotide polymorphism.
Table 2 Allele frequencies of the risk haplotype in (A) 1114 psoriasis
patients and 937 controls and (B) carriers of the PSORS1 risk allele (633
psoriasis patients and 131 control individuals) and results of x
2 statistics
Haplotype(s)
Controls Psoriasis
vulgaris
p Value OR (95% CI) n (%) n (%)
(A)
TAGGTAGCG 552.6 (29.5) 698.7 (31.4) NS NA
S non-risk 1320.6 (70.5) 1526.5 (68.6)
(B)
TAGGTAGCG 64.7 (24.7) 403 (31.8) 0.012 1.42 (1.05 to 1.93)
S non-risk 197.2 (75.3) 864.3 (68.2)
CI, confidence interval; NA, not applicable; NS, not significant; OR, odds ratio.
Figure 4 Electrophoresis of conventional reverse transcriptase
polymerase chain reaction (RT-PCR) products demonstrating expected
amplicon sizes of a product for each (a) GAPDH and (b) MUC16 (primers
in exons 4+5, PCR product of 363 bp), amplified from cDNAs of different
tissues: lane 1: size standard, 2: skin, 3: thymus, 4: thyroid, 5: blood
leucocytes, 6: non-template control.
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742 J Med Genet 2009;46:736–744. doi:10.1136/jmg.2008.065029Furthermore, SNP chip analyses in a further 158 individuals were
normal with regard to CNV of this region. Therefore, we can
probably exclude a CNV of the adjacent region as an explanation
for the association findings. In order to clarify the potential role of
MUC16 in psoriasis and to identify the causal variant(s) at this
locus, further functional studies are necessary.
In summary, we identified a susceptibility factor at PSORS6
that is relevant in patients with type I psoriasis carrying the
PSORS1 risk allele. This risk factor might modify the expression
of neighbouring genes—for example, MUC16—in patients
carrying this risk factor.
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